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Introduction
Pancreatic cancer develops from cancerous cells in the tissues of the pancreas, a gland organ that lies inferior to the stomach. It is one of the most lethal cancers. According to the American Cancer Society, pancreatic cancer is expected to cause 48,960 new cases and 40,560 deaths in the United States in 2015 alone (1) . Only 20% of patients live for more than a year after diagnosis and fewer than 6% survive past five years (2) . Recent evidence suggests the existence of a small population of tumorigenic stem cells responsible for tumor initiation, resistance to chemotherapy and radiation, and metastasis. These cancer stem cells have the ability to self-renew, driving tumorigenicity, recurrence, and metastasis. They also have the capacity to differentiate aberrantly which gives rise to a heterogeneous subpopulation of cancer cells that constitute the bulk of the tumor. Surface markers cluster of differentiation 24 (CD24) and cluster of differentiation 44 (CD44), along with aldehyde dehydrogenase (ALDH1), a detoxifying enzyme responsible for the oxidation of intracellular aldehydes, have been identified as markers of stem cells of pancreatic adenocarcinomas (3, 4) . The role of signal transducers and activators of transcription 3 (STAT3) in pancreatic cancer stem cells, however, is still unknown. Hence, it is important to identify the regulatory mechanisms and signaling pathways involved in pancreatic cancer stem cells and develop novel agents to target pancreatic cancer stem cell populations.
The 
Materials and methods
Pancreatic cancer cell lines. Human pancreatic cancer cell lines (Panc-1, BxPC3, and HPAC) were purchased from the American Type Culture Collection and maintained in Dulbecco's modified Eagle's medium supplemented with 10% FBS, 4.5 g/l L-glutamine, sodium pyruvate, and 1% penicillin/streptomycin. All cell lines were stored in a humidified 37˚C incubator with 5% CO 2 . Cancer stem-like cells were grown in a serum-free mammary epithelial basal medium (MEBM) (Clonetics Division of Cambrex BioScience) supplemented with B27 (Invitrogen), 20 ng/ml EGF (BD Biosciences), 4 µg/ml gentamycin, 1 ng/ml hydrocortisone, 5 µg/ml insulin and 100 µM β-mercaptoethanol (Sigma-Aldrich). (17) that selectively target STAT3, were synthesized by Dr Pui-Kai Li's laboratory at the Ohio State University College of Pharmacy. Stattic, a previously reported STAT3 inhibitor (18) , was purchased from Calbiochem (San Diego, CA, USA).
STAT3 inhibitors, LLL12, FLLL32 and Stattic. Small molecules, LLL12 (16) and FLLL32
MTT cell viability assay. Pancreatic cancer stem-like cells (3,000/well in 96-well plates) were incubated with desired concentrations of compounds in triplicate at 37˚C for 72 h. 3-(4,5-Dimethylthiazolyl)-2,5-diphenyltetrazolium bromide (MTT) viability assays were done and the absorbance was read at 595 nm.
Isolation of cancer stem cells. The AldeFluor kit (StemCell Technologies, Durham, NC, USA) was used to isolate the population of cells with high ALDH enzymatic activity as previously described (19) (20) (21) . Briefly, cells were trypsinized to single cells using 0.05% trypsin and subsequently suspended in AldeFluor assay buffer containing ALDH substrate (BAAA, 1 µmol/l per 1x10 6 cells) and then incubated for 40 min at 37˚C. For each sample, an aliquot of cells was stained under identical conditions with 15 mmol/l diethylaminobenzaldehyde (DEAB), a specific ALDH inhibitor, as a negative control. In all experiments, the AldeFluor-stained cells treated with DEAB served as ALDH-negative controls. Anti-human PE-CD24 and PE/Cy5-CD44 antibodies (BioLegend) were used for CD44/CD24 identification. + /CD24 + Panc-1 and HPAC pancreatic cancer cells were lysed in cold RIPA lysis buffer containing protease inhibitors and subjected to SDS-PAGE. Proteins were transferred on to PVDF membrane and probed with antibodies (Cell Signaling Technology). Membranes were probed with a 1:1,000 dilution of antibodies (Cell Signaling Technology) against phosphospecific STAT3 (tyrosine 705), phospho-independent STAT3, phospho-specific ERK1/2 (threonine 202/tyrosine 204), and GAPDH. Membranes were analyzed using enhanced chemiluminescence Plus reagents and scanned with the Storm Scanner (Amersham Pharmacia Biotech Inc., Piscataway, NJ, USA).
Reverse transcriptase-polymerase chain reaction (RT-PCR).
ALDH + and CD44 + /CD24 + subpopulations of Panc-1 and HPAC pancreatic cancer cells were treated with LLL12 (5 µM), FLLL32 (5 µM), or DMSO for 24 h. RNA was then collected using RNeasy kits (Qiagen, Valencia, CA, USA). PCR amplification was done under the following conditions: 5 min at 94˚C followed by 25 cycles of 30 sec at 94˚C, 30 sec at 55˚C, and 30 sec at 72˚C with a final extension of 5 min at 72˚C. Primer sequences and source information of STAT3 downstream target genes can be found in Table I .
Tumorsphere culture. The ALDH + and CD44 + /CD24 + subpopulations of Panc-1, BxPC3, and HPAC pancreatic cancer cells were plated as single cells in ultra-low attachment 6-well plates (Corning, Lowell, MA, USA) at a density of 25,000 viable cells/well. Cells were grown in a serum-free mammary epithelial basal medium (MEBM) in a humidified incubator (5% CO 2 ) at 37˚C. On the second day after seeding, the ALDH and CD44 -/CD24 -cells were plated as single cells in ultra-low attachment six-well plates at a density of 1,000 or 2,500 viable cells/well in triplicate in MEBM. Three to four weeks later, the content of all wells was collected, pooled, and transferred onto a collagen-coated 6-well dish in differentiating medium (DMEM+10% FBS). Tumorspheres adhered in these conditions in ~24 h, after which they were stained with crystal violet and counted under low magnification. Fig. 2A) and CD44 -/CD24 -subpopulations (Fig. 2B) . Phosphorylation of tyrosine residue 705 (Y705) is important for the activation of STAT3 (22) . In contrast to the differences in STAT3 phosphorylation, the phosphorylation of P-ERK1/2 (T202/Y204) in the ALDH + and ALDH -subpopulation were relatively similar in the three cell lines (Fig. 2A) . The phosphorylation of P-ERK1/2 (T202/Y204) in the CD44 + /CD24 + and CD44 -/CD24 -subpopulations were also similar in all three cell lines except HPAC (Fig. 2B) . These results suggest that the STAT3 pathway plays an important role in pancreatic cancer stem-like cells and thus may serve as attractive pathway for targeting stem cell-like pancreatic cancer populations. (Fig. 3A) and CD44 + /CD24 + subpopulations (Fig. 3B) . Stattic also inhibited STAT3 phosphorylation (Y705) in ALDH + (Fig. 3C ) and CD44 + /CD24 + (Fig. 3D ) subpopulations of Panc-1 and HPAC pancreatic cancer cell lines at a higher concentration (20 µM). LLL12, FLLL32, and Stattic selectively inhibited P-STAT3 as demonstrated by the lack of inhibition of P-ERK1/2 in both ALDH + and CD44 + /CD24 + subpopulations of Panc-1 and HPAC (Fig. 3) . (Fig. 4B ) pancreatic cancer stem-like cells related to cancer cell proliferation, survival, and angiogenesis, such as Cyclin D, Survivin, and Bcl-XL. Furthermore, LLL12 and FLLL32 inhibited Notch1 and Notch3 expression in ALDH + (Fig. 4A ) and CD44 + /CD24 + cells (Fig. 4B) , which have recently been reported as putative STAT3 downstream target genes (23, 24) . The Notch signaling pathway is known to be essential for normal stem cell selfrenewal and differentiation in a variety of tissues, and is involved in the human cancer stem cell self-renewal capacity and tumorigenicity. (Fig. 6A and B) . As previously demonstrated, Stattic was not as potent in inhibiting tumorsphere forming capacity as LLL12 and FLLL32 in the ALDH + and CD44 + /CD24 + subpopulations (Fig. 6) . Thus, we demonstrated that pancreatic cancer stem-like cells in the viability and tumorsphere forming ability, which indicates that STAT3 is an important pathway in pancreatic stem-like cancer cells and thus may serve as an attractive target for therapeutic drugs.
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Discussion
Presently, the STAT3 pathway has been characterized in many cancers and the main effort to target constitutive In conclusion, this study demonstrates that STAT3 is activated in pancreatic cancer stem-like cells and that constitutively activated STAT3 in these cells enhances proliferation and survival. Our results show that STAT3 inhibition by small molecules could inhibit tumor stem-like cell growth, cell viability, and tumorsphere formation. Targeting STAT3 may provide an effective method for depleting stem celllike pancreatic cancer cells and thus an effective treatment for pancreatic cancer. Our study also demonstrated that both LLL12 and FLLL32 significantly inhibited STAT3 in pancreatic cancer stem-like cells and thus are promising drug candidates for targeting constitutive STAT3 expression in these cells.
